Modeling, Synthesis, and Biological Evaluation of Potential Retinoid X Receptor (RXR)-Selective Agonists: Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(5,5,8,8-tetrahydronaphthalen-2-yl)amino)nicotinic Acid (NEt-TMN). 2016

Michael C Heck, and Carl E Wagner, and Pritika H Shahani, and Mairi MacNeill, and Aleksandra Grozic, and Tamana Darwaiz, and Micah Shimabuku, and David G Deans, and Nathan M Robinson, and Samer H Salama, and Joseph W Ziller, and Ning Ma, and Arjan van der Vaart, and Pamela A Marshall, and Peter W Jurutka
School of Mathematical and Natural Sciences, New College of Interdisciplinary Arts and Sciences, Arizona State University , 4701 West Thunderbird Road, Glendale, Arizona 85306, United States.

Sulfonic acid analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene, 1) as well as seven novel and two reported analogues of 6-(ethyl(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)amino)nicotinic acid (NEt-TMN) were synthesized and assessed for selective retinoid X receptor (RXR) agonism. Compound 1 is FDA-approved for treatment of cutaneous T-cell lymphoma (CTCL); however, 1 can provoke side effects by impacting RXR-dependent receptor pathways. All of the analogues in this study were evaluated for their potential to bind RXR through modeling and then assayed in an RXR-RXR mammalian-2-hybrid (M2H) system and in RXR-responsive element (RXRE)-mediated transcriptional experiments. The EC50 profiles for these unique analogues and their analogous effectiveness to inhibit proliferation in CTCL cells relative to 1 suggest that these compounds possess similar or even enhanced therapeutic potential. Several compounds also displayed more selective RXR activation with minimal cross-signaling of the retinoic acid receptor. These results suggest that modifications of potent RXR agonists such as NEt-TMN can lead to improved biological selectivity and potency compared with the known therapeutic.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009525 Niacin A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties. Nicotinic Acid,3-Pyridinecarboxylic Acid,Enduracin,Induracin,Lithium Nicotinate,Niacin Aluminum Salt,Niacin Ammonium Salt,Niacin Calcium Salt,Niacin Cobalt (2+) Salt,Niacin Copper (2+) Salt,Niacin Hydrochloride,Niacin Iron (2+) Salt,Niacin Lithium Salt,Niacin Lithium Salt, Hemihydrate,Niacin Magnesium Salt,Niacin Manganese (2+) Salt,Niacin Potassium Salt,Niacin Sodium Salt,Niacin Tartrate,Niacin Tosylate,Niacin Zinc Salt,Nicamin,Nico-400,Nicobid,Nicocap,Nicolar,Nicotinate,Wampocap,3 Pyridinecarboxylic Acid,Aluminum Salt, Niacin,Hydrochloride, Niacin,Nico 400,Nico400,Nicotinate, Lithium,Potassium Salt, Niacin,Sodium Salt, Niacin,Tartrate, Niacin,Tosylate, Niacin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077610 Bexarotene A rexinoid (an RXR-binding ligand), tetrahydronaphthalene derivative and RETINOID X RECEPTOR antagonist that is used in the treatment of CUTANEOUS T-CELL LYMPHOMA. 3-methyl-TTNEB,4-(1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid,LG69 compound,LGD 1069,LGD-1069,LGD1069,Targretin
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013764 Tetrahydronaphthalenes Partially saturated 1,2,3,4-tetrahydronaphthalene compounds. Tetralins
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D016410 Lymphoma, T-Cell, Cutaneous A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders. Granulomatous Slack Skin,T-Cell Lymphoma, Cutaneous,Cutaneous T-Cell Lymphoma,Lymphoma, T Cell, Cutaneous,Cutaneous T Cell Lymphoma,Cutaneous T-Cell Lymphomas,Lymphoma, Cutaneous T-Cell,Lymphomas, Cutaneous T-Cell,Slack Skin, Granulomatous,T Cell Lymphoma, Cutaneous,T-Cell Lymphomas, Cutaneous
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D047488 Retinoid X Receptors A subtype of RETINOIC ACID RECEPTORS that are specific for 9-cis-retinoic acid which function as nuclear TRANSCRIPTION FACTORS that regulate multiple signaling pathways. Retinoid X Receptor,9-cis-Retinoic Acid Receptor,RXR Protein,Receptor, Retinoid X,XR78E-F protein,Protein, RXR,Receptor, 9-cis-Retinoic Acid,Receptors, Retinoid X,XR78E F protein,protein, XR78E-F

Related Publications

Michael C Heck, and Carl E Wagner, and Pritika H Shahani, and Mairi MacNeill, and Aleksandra Grozic, and Tamana Darwaiz, and Micah Shimabuku, and David G Deans, and Nathan M Robinson, and Samer H Salama, and Joseph W Ziller, and Ning Ma, and Arjan van der Vaart, and Pamela A Marshall, and Peter W Jurutka
October 2009, Journal of medicinal chemistry,
Michael C Heck, and Carl E Wagner, and Pritika H Shahani, and Mairi MacNeill, and Aleksandra Grozic, and Tamana Darwaiz, and Micah Shimabuku, and David G Deans, and Nathan M Robinson, and Samer H Salama, and Joseph W Ziller, and Ning Ma, and Arjan van der Vaart, and Pamela A Marshall, and Peter W Jurutka
September 2012, ChemMedChem,
Michael C Heck, and Carl E Wagner, and Pritika H Shahani, and Mairi MacNeill, and Aleksandra Grozic, and Tamana Darwaiz, and Micah Shimabuku, and David G Deans, and Nathan M Robinson, and Samer H Salama, and Joseph W Ziller, and Ning Ma, and Arjan van der Vaart, and Pamela A Marshall, and Peter W Jurutka
November 2021, International journal of molecular sciences,
Michael C Heck, and Carl E Wagner, and Pritika H Shahani, and Mairi MacNeill, and Aleksandra Grozic, and Tamana Darwaiz, and Micah Shimabuku, and David G Deans, and Nathan M Robinson, and Samer H Salama, and Joseph W Ziller, and Ning Ma, and Arjan van der Vaart, and Pamela A Marshall, and Peter W Jurutka
November 2013, Journal of medicinal chemistry,
Michael C Heck, and Carl E Wagner, and Pritika H Shahani, and Mairi MacNeill, and Aleksandra Grozic, and Tamana Darwaiz, and Micah Shimabuku, and David G Deans, and Nathan M Robinson, and Samer H Salama, and Joseph W Ziller, and Ning Ma, and Arjan van der Vaart, and Pamela A Marshall, and Peter W Jurutka
June 2000, Bioorganic & medicinal chemistry letters,
Michael C Heck, and Carl E Wagner, and Pritika H Shahani, and Mairi MacNeill, and Aleksandra Grozic, and Tamana Darwaiz, and Micah Shimabuku, and David G Deans, and Nathan M Robinson, and Samer H Salama, and Joseph W Ziller, and Ning Ma, and Arjan van der Vaart, and Pamela A Marshall, and Peter W Jurutka
March 2013, Journal of medicinal chemistry,
Michael C Heck, and Carl E Wagner, and Pritika H Shahani, and Mairi MacNeill, and Aleksandra Grozic, and Tamana Darwaiz, and Micah Shimabuku, and David G Deans, and Nathan M Robinson, and Samer H Salama, and Joseph W Ziller, and Ning Ma, and Arjan van der Vaart, and Pamela A Marshall, and Peter W Jurutka
December 2022, International journal of molecular sciences,
Michael C Heck, and Carl E Wagner, and Pritika H Shahani, and Mairi MacNeill, and Aleksandra Grozic, and Tamana Darwaiz, and Micah Shimabuku, and David G Deans, and Nathan M Robinson, and Samer H Salama, and Joseph W Ziller, and Ning Ma, and Arjan van der Vaart, and Pamela A Marshall, and Peter W Jurutka
August 2017, Journal of medicinal chemistry,
Michael C Heck, and Carl E Wagner, and Pritika H Shahani, and Mairi MacNeill, and Aleksandra Grozic, and Tamana Darwaiz, and Micah Shimabuku, and David G Deans, and Nathan M Robinson, and Samer H Salama, and Joseph W Ziller, and Ning Ma, and Arjan van der Vaart, and Pamela A Marshall, and Peter W Jurutka
May 2019, Journal of medicinal chemistry,
Michael C Heck, and Carl E Wagner, and Pritika H Shahani, and Mairi MacNeill, and Aleksandra Grozic, and Tamana Darwaiz, and Micah Shimabuku, and David G Deans, and Nathan M Robinson, and Samer H Salama, and Joseph W Ziller, and Ning Ma, and Arjan van der Vaart, and Pamela A Marshall, and Peter W Jurutka
March 1997, Arzneimittel-Forschung,
Copied contents to your clipboard!